Novo Nordisk (NVO) CFO Karsten Munk Knudsen is skeptical that President Trump’s executive order to reduce the time it takes to approve manufacturing plants in the country will significantly change timelines for the pharmaceutical industry, Reuters’ Maggie Fick and Jacob Gronholt-Pedersen report. Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharma plants in the U.S., as part of new regulations to encourage domestic manufacturing. Knudsen noted that it takes years for a pharmaceutical company to build a factory in compliance with the quality protocols set and enforced by the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Morning Movers: Disney jumps after first quarter earnings, Abu Dhabi resort plan
- Novo Nordisk Reports Strong Q1 2025 Results Amid Adjusted Outlook
- Novo Nordisk cuts FY25 revenue growth view of 13%-21% from 16%-24%
- Novo Nordisk up 5% at $69.80 after Q1 results and guidance
- Novo Nordisk reports Q1 operating profit DKK 38.8B, up 22% y/y